Results 71 to 80 of about 10,751 (182)

Atezolizumab Plus Bevacizumab Treatment for Patients With Hepatocellular Carcinoma in the Barcelona Clinic Liver Cancer B2 Stage

Journal of Gastroenterology and Hepatology, Volume 41, Issue 11, Page 3567-3574, November 2026.
ABSTRACT Background and Aim The optimal treatment strategy for patients with intermediate‐stage hepatocellular carcinoma beyond the up‐to‐seven criteria (Barcelona Clinic Liver Cancer B2) remains uncertain. Although transarterial chemoembolization has long been the standard of care, its efficacy is limited in this subgroup, and systemic therapies have ...
Keishi Ouchi, Masashi Ninomiya, Mio Tsuruoka, Jun Inoue, Atsushi Hiraoka, Kosuke Sato, Kotaro Doi, Kengo Watanabe, Tomoya Sasazaki, Takayoshi Oikawa, Kei Endo, Tamami Abe, Masashi Fujita, Kazumichi Abe, Tomohiro Katsumi, Wataru Sato, Chikara Iino, Nobukazu Tanabe, Hiroshi Numao, Hiromasa Ohira, Hidekatsu Kuroda, Yoshiyuki Ueno, Atsushi Masamune   +22 more
wiley   +1 more source

Molecular Mechanisms and Therapeutic Advances in KRAS G12C‐Mutant Non‐Small Cell Lung Cancer: Toward Mechanism‐Guided Longitudinal Management

Cancer Innovation, Volume 5, Issue 5, October 2026.
This review summarizes the molecular mechanisms, clinical development, resistance patterns, and emerging treatment strategies of KRAS G12C‐mutated non‐small cell lung cancer, with emphasis on approved inhibitors, combination approaches, next‐generation agents, and future directions from both global and Chinese perspectives.
Haiying Wang, Hanxiao Chen, Sheng Li, Jun Zhao   +3 more
wiley   +1 more source

Beyond the Monolayer: Leveraging 3D Culture Systems to Decode Mechanisms of Drug Resistance and Therapeutic Vulnerabilities in Colorectal Cancer

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Two‐dimensional (2D) monolayer cultures remain the workhorse of colorectal cancer (CRC) research and high‐throughput screening (HTS), yet they poorly recapitulate tissue architecture, extracellular matrix (ECM) cues, metabolic gradients, and multicellular heterogeneity that govern drug response in vivo. Over the past decade, three‐dimensional (
Sarah J. Harmych, Bhuminder Singh
wiley   +1 more source

Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial

Bladder Cancer, 2020
BACKGROUND: The phase 3 RANGE trial found ramucirumab/docetaxel improved progression-free survival (PFS) versus placebo/docetaxel (median 4.1 vs 2.8 months; hazard ratio [HR] = 0.757, p  = 0.0118) for treatment of platinum-refractory metastatic ...
Alexandra Drakaki, Conor J. Kirby, Michiel S. van der Heijden, Daniel P. Petrylak, Thomas Powles, Kim N. Chi, Aude Fléchon, Andrea Necchi, Lajos Géczi, Jae-Lyun Lee, Georgios Gakis, Sergio Bracarda, Simon Chowdhury, Chia-Chi Lin, Daniel Keizman, Ulka N. Vaishampayan, Annamaria H. Zimmermann, Katherine Bell-McGuinn, Daniel Castellano   +18 more
doaj   +1 more source

Artificial Intelligence in Gastric Cancer: Diagnostic, Prognostic, and Predictive Developments, Evidence Maturity, and Translational Challenges

Cancer Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background Gastric cancer (GC) remains a major global health burden characterized by substantial heterogeneity in diagnosis, prognosis, and treatment response. Artificial intelligence (AI), including machine learning (ML) and deep learning (DL), has been increasingly investigated for the analysis of endoscopic images, radiological scans, whole‐
Chong Chen, Weisong Xu, Tong Wu, Junpeng Zhao, Xuebing Xu, Mingbing Xiao, Kang Xu   +6 more
wiley   +1 more source

A NEW NP-UPLC METHOD FOR THE SEPARATION AND SIMULTANEOUS QUANTIFICATION OF RAMUCIRUMAB AND ERLOTINIB [PDF]

, 2021
Objective: This investigation demonstrates a stability-indicating and reliable “normal phase ultra-performance liquid chromatography” method to simultaneously quantify Ramucirumab and Erlotinib in the pharmaceutical dosage form.
CHAITANYA, SIVA MADHU, GANDHAM, SATYA LAKSHMI, NISSANKARARAO, SRINATH   +2 more
core   +1 more source

Endoscopic Ultrasound-Guided Drainage of Intra-Abdominal Abscess after Gastric Perforation in a Patient Receiving Ramucirumab and Paclitaxel for Advanced Gastric Cancer

Case Reports in Oncology, 2017
Gastrointestinal perforation is a serious adverse event that occurs in approximately 1% of patients receiving ramucirumab and paclitaxel. A 67-year-old man with unresectable advanced gastric cancer was admitted to our hospital and treated with ...
Koichiro Mandai, Atsushi Shirakawa, Koji Uno, Kenjiro Yasuda   +3 more
doaj   +1 more source

Human biomarker navigator

iMeta, Volume 5, Issue 5, October 2026.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li, Qian Zhang, Zijie Wang, Zeping Gui, Jing Liu, Jingda Li, Maojun Jiang, Zukang Chang, Qingqing Han, Bendong Yang, Tariq Saeed, Jun Li, Jinghan Jia, Chenghu Song, Tong Shao, Tianhuan Peng, Xueying Zhang, Pingping Guo, Jun Luo, Gangao Yang, Yuan Wan, Gokhan Zengin, Quan Yuan, Lingru Li, Xiaohui Fan, Yang Luo, Lvyun Zhu, Yanfei Zheng, Wenjun Mao, Wenlong Sun   +29 more
wiley   +1 more source

Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers

, 2015
Hesham ElHalawani, Omar Abdel-Rahman Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt Abstract: Gastric (GC) and gastroesophageal junction (GEJ) cancers are two global health problems with a relatively high ...
ElHalawani H, Abdel-Rahman O
core  

Colorectal Cancer: Epidemiology, Risk Factors, Signaling Pathways, Clinical Features, Screening, Diagnosis, and Management

MedComm, Volume 7, Issue 10, October 2026.
Colorectal cancer is a heterogeneous, adaptive disease shaped by population‐level risk, genomic and epigenetic alterations, tumor ecosystem evolution, and treatment pressure. This review integrates epidemiology, risk factors, signaling networks, clinical presentation, screening, molecular diagnosis, and stage‐ and biomarker‐guided management while ...
Kairui Wan, Ke Tang, Linglong Wang, Qin Tian, Mingwei Zheng, Cheng Qian, Limei Liu   +6 more
wiley   +1 more source